HomeCompareSRRA vs MCD

SRRA vs MCD: Dividend Comparison 2026

SRRA yields 3.64% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCD wins by $53.2K in total portfolio value· pulled ahead in Year 4
10 years
SRRA
SRRA
● Live price
3.64%
Share price
$54.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$459.50
Full SRRA calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — SRRA vs MCD

📍 MCD pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRRAMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRRA + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRRA pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRRA
Annual income on $10K today (after 15% tax)
$309.15/yr
After 10yr DRIP, annual income (after tax)
$390.58/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, MCD beats the other by $21,902.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRRA + MCD for your $10,000?

SRRA: 50%MCD: 50%
100% MCD50/50100% SRRA
Portfolio after 10yr
$51.9K
Annual income
$13,343.60/yr
Blended yield
25.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

SRRA
No analyst data
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRRA buys
0
MCD buys
0
No recent congressional trades found for SRRA or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRRAMCD
Forward yield3.64%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$25.3K$78.5K
Annual income after 10y$459.50$26,227.70
Total dividends collected$4.1K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: SRRA vs MCD ($10,000, DRIP)

YearSRRA PortfolioSRRA Income/yrMCD PortfolioMCD Income/yrGap
1$11,064$363.70$10,815$334.85+$249.00SRRA
2$12,214$376.07$11,826$491.71+$388.00SRRA
3$13,457$388.01$13,123$730.06+$334.00SRRA
4← crossover$14,799$399.53$14,853$1,100.07$54.00MCD
5$16,245$410.62$17,257$1,690.61$1.0KMCD
6$17,804$421.26$20,752$2,667.01$2.9KMCD
7$19,481$431.47$26,103$4,354.83$6.6KMCD
8$21,286$441.25$34,794$7,437.78$13.5KMCD
9$23,227$450.59$49,926$13,461.60$26.7KMCD
10$25,312$459.50$78,550$26,227.70$53.2KMCD

SRRA vs MCD: Complete Analysis 2026

SRRAStock

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.

Full SRRA Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this SRRA vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRRA vs SCHDSRRA vs JEPISRRA vs OSRRA vs KOSRRA vs MAINSRRA vs YUMSRRA vs QSRSRRA vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.